Posted on

cbd oil canada stock

In 2019, Tilray generated nearly $167 million in revenues. Its head office is located in Toronto, with products being sold in the United States, Australia, New Zealand, Germany, Portugal and Latin America.

As a result of such growth, an analysis of its stocks between 2012 and 2019 shows a very significant price increase: whereas in 2012, a company share had a price of $10.36, in 2019, the same stock went up to $107.50.

Cara Therapeutics is currently developing new products without same side effects of traditional pain medications, such as morphine, ibuprofen, and acetaminophen. In fact, the company’s goal is to use marijuana for pain management, working on cannabinoid receptors to influence patient’ reactions to pain and inflammation. This is why the company has developed an experimental cannabinoid drug, called CR701, which could prove very effective in treating chronic pain, without the addictive side effects typical of other pain relievers.


Cara Therapeutics is a U.S. bio-pharmaceutical company founded in 2004, which specialises in the distribution of products for the relief of acute and chronic pain and itching; its drug uses a new approach to pain management that primarily relies on kappa opioid receptors.

Aurora Cannabis was founded in Canada in 2016 by a group of investors, who were able to secure a plot of over 160 acres of land in Mountain View County, where the company’s first facility was located. The company was licensed to grow cannabis in 2014, making it the first cannabis producer to obtain a federal license in that province. On November 2014, Aurora Cannabis was issued the first Health Canada license for the sale of medical marijuana.

Cronos Group, which was founded in 2012, is a Canadian producer with a strong international presence through subsidiaries and licensed producers. It uses multiple international production and distribution platforms and is fully committed to products research and development, to the establishment of international brands, and to the development of intellectual properties. The company has built a global network based on partnership, joint ventures, and product manufacturing and distribution across 5 continents.

Most companies are involved in the production of medical marijuana, since cannabis-based products seems to have positive effects on people suffering from a variety of medical conditions. Preliminary research suggests that cannabis can reduce nausea during chemotherapy, improve appetite in people with HIV/AIDS, reduce chronic pain and muscle spasms, and even treat severe forms of epilepsy. Furthermore, marijuana appears to be a great muscle relaxant, capable of lessening the tremors associated with Parkinson’s disease. Nowadays, many pharmaceutical companies are involved in the production of medicinal cannabis.

Marijuana stocks, as represented by the ETFMG Alternative Harvest ETF (MJ), have slightly outperformed the broader market. MJ has provided a total return of 36.9% over the past 12 months, above the Russell 1000 index’s total return of 35.0%. These market performance numbers and all statistics in the tables below are as of Aug. 23, 2021.

The marijuana industry is made up of companies that either support or are engaged in the research, development, distribution, and sale of medical and recreational marijuana. Cannabis has begun to gain wider acceptance and has been legalized in a growing number of nations, states, and other jurisdictions for recreational, medicinal, and other uses. Some of the biggest companies in the marijuana industry include Canopy Growth Corp. (CGC), Cronos Group Inc. (CRON), and Tilray Inc. (TLRY). Many big marijuana companies have continued to post sizable net losses as they focus on investing in equipment to speed up revenue growth.

HITI.V is top for value and JUSH.CX is top for growth and momentum

These are the marijuana stocks with the highest year-over-year (YOY) sales growth for the most recent quarter. Rising sales can help investors identify companies that are able to grow revenue organically or through other means, and find growing companies that have not yet reached profitability. In addition, earnings per share can be significantly influenced by accounting factors that may not reflect the overall strength of the business. However, sales growth can also be potentially misleading about the strength of a business, because growing sales on money-losing businesses can be harmful if the company has no plan to reach profitability.

These are the marijuana stocks with the lowest 12-month trailing price-to-sales (P/S) ratio. For companies in the early stages of development or industries suffering from major shocks, this can be substituted as a rough measure of a business’s value. A business with higher sales could eventually produce more profit when it achieves, or returns to, profitability. The P/S ratio shows how much you’re paying for the stock for each dollar of sales generated.

Here are the top 5 marijuana stocks with the best value, the fastest growth, and the most momentum.

Market Cap: $11.357B

The United States and Canada may share a border, but there are very inherent differences in how each country views and treats marijuana. The U.S. has been plagued with many restrictions because marijuana is still considered a controlled substance at the federal level. As of November 2020, a total of 35 states as well as the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands allow pot for medical use.   And many states are still grappling with the issue of recreational usage.

3. Aphria

Market Cap: $28.24M

Market Cap: $1.621B

Here’s a look at some of those companies. All figures are accurate as of November 2020.